Redeye updated its estimates and fair value range following Heliospectra’s Q4 2024 report and the fully secured rights issue of SEK 25.6m, expected to be completed by the end of Q1. Although the Q4 report was softer than expected, the fundamentals are in place for accelerated growth. With strengthened financials, expanded commercial efforts, and ongoing product innovation, Heliospectra is well-positioned to seize market opportunities and drive increased growth in 2025

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/